Lapatinib induces mitochondrial dysfunction to enhance oxidative stress and ferroptosis in doxorubicin-induced cardiomyocytes via inhibition of PI3K/AKT signaling pathway

References

• Carvalho FS, Burgeiro A, Garcia R, et al. Doxorubicin-induced cardiotoxicity: from bioenergetic failure and cell death to cardiomyopathy. Med Res Rev. 2014;34(1):106–135.
   PubMed Web of Science ®Google Scholar
• Shabalala S, Muller CJF, Louw J, et al. Polyphenols, autophagy and doxorubicin-induced cardiotoxicity. Life Sci. 2017;180:160–170.
   PubMed Web of Science ®Google Scholar
• Deng J, Huang M, Wu H. Protective effect of limonin against doxorubicin-induced cardiotoxicity via activating nuclear factor - like 2 and Sirtuin 2 signaling pathways. Bioengineered. 2021;12(1):7975–7984.
   PubMed Web of Science ®Google Scholar
• Songbo M, Lang H, Xinyong C, et al. Oxidative stress injury in doxorubicin-induced cardiotoxicity. Toxicol Lett. 2019;307:41–48.
   PubMed Web of Science ®Google Scholar
• Wenningmann N, Knapp M, Ande A, et al. Insights into doxorubicin-induced cardiotoxicity: molecular mechanisms, preventive strategies, and early monitoring. Mol Pharmacol. 2019;96(2):219–232.
   PubMed Web of Science ®Google Scholar
• D’Amato V, Raimondo L, Formisano L, et al. Mechanisms of lapatinib resistance in HER2-driven breast cancer. Cancer Treat Rev. 2015;41(10):877–883.
   PubMed Web of Science ®Google Scholar
• Bonnefoi H, Jacot W, Saghatchian M, et al. Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study. Ann Oncol. 2015;26(2):325–332.
   PubMed Web of Science ®Google Scholar
• Hasinoff BB, Patel D, Wu X. The dual-targeted HER1/HER2 tyrosine kinase inhibitor lapatinib strongly potentiates the cardiac myocyte-damaging effects of doxorubicin. Cardiovasc Toxicol. 2013;13(1):33–47.
   PubMed Web of Science ®Google Scholar
• Yang B, Papoian T. Tyrosine kinase inhibitor (TKI)-induced cardiotoxicity: approaches to narrow the gaps between preclinical safety evaluation and clinical outcome. J Appl Toxicol. 2012;32(12):945–951.
   PubMed Web of Science ®Google Scholar
• Wang H, Li F, Du C, et al. Doxorubicin and lapatinib combination nanomedicine for treating resistant breast cancer. Mol Pharm. 2014;11(8):2600–2611.
   PubMed Web of Science ®Google Scholar
• Hsu WT, Huang CY, Yen CYT, et al. The HER2 inhibitor lapatinib potentiates doxorubicin-induced cardiotoxicity through iNOS signaling. Theranostics. 2018;8:3176–3188.
   PubMed Web of Science ®Google Scholar
• Zhao L, Qi Y, Xu L, et al. MicroRNA-140-5p aggravates doxorubicin-induced cardiotoxicity by promoting myocardial oxidative stress via targeting Nrf2 and Sirt2. Redox Biol. 2018;15:284–296.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Zhang Q. Catalpol ameliorates doxorubicin-induced inflammation and oxidative stress in H9C2 cells through PPAR-γ activation. Exp Ther Med. 2020;20:1003–1011.
   PubMed Web of Science ®Google Scholar
• Zhao L, Tao X, Qi Y, et al. Protective effect of dioscin against doxorubicin-induced cardiotoxicity via adjusting microRNA-140-5p-mediated myocardial oxidative stress. Redox Biol. 2018;16:189–198.
   PubMed Web of Science ®Google Scholar
• Li HR, Wang C, Sun P, et al. Melatonin attenuates doxorubicin-induced cardiotoxicity through preservation of YAP expression. J Cell Mol Med. 2020;24:3634–3646.
   PubMed Web of Science ®Google Scholar
• Vishnu KV, Ajeesh Kumar KK, Chatterjee NS, et al. Sardine oil loaded vanillic acid grafted chitosan microparticles, a new functional food ingredient: attenuates myocardial oxidative stress and apoptosis in cardiomyoblast cell lines (H9c2). Cell Stress Chaperones. 2018;23(2):213–222.
   PubMed Web of Science ®Google Scholar
• Subbarao RB, Ok SH, Lee SH, et al. Lipid emulsion inhibits the late apoptosis/cardiotoxicity induced by doxorubicin in rat cardiomyoblasts. Cells. 2018;7:144.
   PubMed Web of Science ®Google Scholar
• Helal M, Alcorn J, Bandy B. Doxorubicin cytotoxicity in differentiated H9c2 cardiomyocytes: evidence for acute mitochondrial superoxide generation. Cardiovasc Toxicol. 2021;21(2):152–161.
   PubMed Web of Science ®Google Scholar
• Xia Y, Chen Z, Chen A, et al. LCZ696 improves cardiac function via alleviating Drp1-mediated mitochondrial dysfunction in mice with doxorubicin-induced dilated cardiomyopathy. J Mol Cell Cardiol. 2017;108:138–148.
   PubMed Web of Science ®Google Scholar
• Yu W, Qin X, Zhang Y, et al. Curcumin suppresses doxorubicin-induced cardiomyocyte pyroptosis via a PI3K/Akt/mTOR-dependent manner. Cardiovasc Diagn Ther. 2020;10(4):752–769.
   PubMed Web of Science ®Google Scholar
• Paech F, Bouitbir J, Krähenbühl S. Hepatocellular toxicity associated with tyrosine kinase inhibitors: mitochondrial damage and inhibition of glycolysis. Front Pharmacol. 2017;8:367.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Hernández MA, de la Cruz-Ojeda P, López-Grueso MJ, et al. Integrated molecular signaling involving mitochondrial dysfunction and alteration of cell metabolism induced by tyrosine kinase inhibitors in cancer. Redox Biol. 2020;36:101510.
   PubMed Web of Science ®Google Scholar
• Wang H, Liu C, Zhao Y, et al. Mitochondria regulation in ferroptosis. Eur J Cell Biol. 2020;99(1):151058.
   PubMed Web of Science ®Google Scholar
• Raschi E, Vasina V, Ursino MG, et al. Anticancer drugs and cardiotoxicity: insights and perspectives in the era of targeted therapy. Pharmacol Ther. 2010;125(2):196–218.
   PubMed Web of Science ®Google Scholar
• Shi W, Deng H, Zhang J, et al. Mitochondria-targeting small molecules effectively prevent cardiotoxicity induced by doxorubicin. Molecules. 2018;23(6):1486.
   PubMed Web of Science ®Google Scholar
• Tadokoro T, Ikeda M, Ide T, et al. Mitochondria-dependent ferroptosis plays a pivotal role in doxorubicin cardiotoxicity. JCI Insight. 2020;5. DOI:10.1172/jci.insight.132747
   PubMed Web of Science ®Google Scholar
• Shadle SE, Bammel BP, Cusack BJ, et al. Daunorubicin cardiotoxicity: evidence for the importance of the quinone moiety in a free-radical-independent mechanism. Biochem Pharmacol. 2000;60:1435–1444.
   PubMed Web of Science ®Google Scholar
• Childs AC, Phaneuf SL, Dirks AJ, et al. Doxorubicin treatment in vivo causes cytochrome C release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2: baxratio. Cancer Res. 2002;62:4592–4598.
   PubMed Web of Science ®Google Scholar
• Tewari SG, Bugenhagen SM, Palmer BM, et al. Dynamics of cross-bridge cycling, ATP hydrolysis, force generation, and deformation in cardiac muscle. J Mol Cell Cardiol. 2016;96:11–25.
   PubMed Web of Science ®Google Scholar
• Wu R, Wang HL, Yu HL, et al. Doxorubicin toxicity changes myocardial energy metabolism in rats. Chem Biol Interact. 2016;244:149–158.
   PubMed Web of Science ®Google Scholar
• Zhang HS, Wang SQ. Nrf2 is involved in the effect of tanshinone IIA on intracellular redox status in human aortic smooth muscle cells. Biochem Pharmacol. 2007;73:1358–1366.
   PubMed Web of Science ®Google Scholar
• Segredo MP, Salvadori DM, Rocha NS, et al. Oxidative stress on cardiotoxicity after treatment with single and multiple doses of doxorubicin. Hum Exp Toxicol. 2014;33:748–760.
   PubMed Web of Science ®Google Scholar
• Mou Y, Wang J, Wu J, et al. Ferroptosis, a new form of cell death: opportunities and challenges in cancer. J Hematol Oncol. 2019;12:34.
   PubMed Web of Science ®Google Scholar
• Xie Y, Hou W, Song X, et al. Ferroptosis: process and function. Cell Death Differ. 2016;23(3):369–379.
   PubMed Web of Science ®Google Scholar
• Stockwell BR, Friedmann Angeli JP, Bayir H, et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 2017;171(2):273–285.
   PubMed Web of Science ®Google Scholar
• Zheng B, Zhou X, Pang L, et al. Baicalin suppresses autophagy-dependent ferroptosis in early brain injury after subarachnoid hemorrhage. Bioengineered. 2021;12(1):7794–7804.
   PubMed Web of Science ®Google Scholar
• Alim I, Caulfield JT, Chen Y, et al. Selenium drives a transcriptional adaptive program to block ferroptosis and treat stroke. Cell. 2019;177(5):1262–1279. e1225.
   PubMed Web of Science ®Google Scholar
• Yuan H, Li X, Zhang X, et al. Identification of ACSL4 as a biomarker and contributor of ferroptosis. Biochem Biophys Res Commun. 2016;478(3):1338–1343.
   PubMed Web of Science ®Google Scholar
• Doll S, Proneth B, Tyurina YY, et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol. 2017;13:91–98.
   PubMed Web of Science ®Google Scholar
• Fang X, Wang H, Han D, et al. Ferroptosis as a target for protection against cardiomyopathy. Proc Natl Acad Sci U S A. 2019;116:2672–2680.
   PubMed Web of Science ®Google Scholar
• Ma S, Henson ES, Chen Y, et al. Ferroptosis is induced following siramesine and lapatinib treatment of breast cancer cells. Cell Death Dis. 2016;7:e2307.
   PubMed Web of Science ®Google Scholar
• Jia Y, Zuo D, Li Z, et al. Astragaloside IV inhibits doxorubicin-induced cardiomyocyte apoptosis mediated by mitochondrial apoptotic pathway via activating the PI3K/Akt pathway. Chem Pharm Bull (Tokyo). 2014;62:45–53.
   PubMed Web of Science ®Google Scholar
• Li B, Ding CM, Li YX, et al. Over-regulation of microRNA-133b inhibits cell proliferation of cisplatin-induced non-small cell lung cancer cells through PI3K/Akt and JAK2/STAT3 signaling pathway by targeting EGFR. Oncol Rep. 2018;39:1227–1234.
   PubMed Web of Science ®Google Scholar